drugset / Trial / NCT01558375

Anakinra in Hidradenitis Suppurativa

NCT01558375

Phase 2 Completed 20 enrolled University of Athens
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Aim of this double-blind, randomized, controlled clinical trial is to compare the safety and the efficacy of anakinra over placebo for the management of patients with hidradenitis suppurativa (HS) of Hurley II and Hurley III disease stage. Patients will be evaluated on subsequent follow-up visits. Two scores will be applied: disease activity as assessed in the protocol by the investigator; and Sartorius score. Primary efficacy endpoint will be the comparisons of visual analogue scores, of disease activity, of Sartorius score and of dermatology life quality index between the two groups of treatment over follow-up.

Timeline

Start
2012-03
Primary completion
2014-02
Completion
2014-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Anakinra Protein / enzyme biologic 100 mg Subcutaneous